Inhibition of IKK complex – Dual inhibition of IκB kinase 1/2 for cancer therapy


Ref.-Nr. 5028

The NF-κB signaling pathway plays a pivotal role in a broad range of cellular processes including cell proliferation and survival and is tightly linked to diseases such as cancer. The invention provides com-positions comprising IKK1 and IKK2 antagonists for use in medical treatments of proliferative disorders, in particular for the treatment of cancer. Most preferred in context of the invention is a gene editing approach for a targeted simultaneous knockout of the genes of IKK1 and IKK2 in a cell associated with the proliferative disorder. 

Keywords: inhibitorische kappa B Kinase, Krebs, Gentherapie, IKK, inhibitory kappa B kinase, cancer, gene therapy, CRISPR/CAS

Simultaneous CRISPR/Cas9-mediated knockout of IKBKA (IKK1) and IKBKB (IKK2) resulted in cells highly sensitized for programmed cell death (apoptotic/necroptotic) after exposure to tumor necrosis factor (TNF)-α. This effect was not observable in single knockouts for either IKK1 or IKK2. Targeting of IKK1 and IKK2 simultaneously, preferably on the genome level, therefore opens up new therapeutic avenues to tackle proliferative disorders such as cancer. Hence, the present methods and compositions provide a means for the selective induction of apoptosis in cells associated with a proliferative disorder, such as tumor cells.

Commercial Opportunities

Novel gene therapy and a novel drug screening concept are offered for licensing.

Competitive Advantages

  • Novel gene therapy for cancer
  • Novel screening strategy
  • Therapy option for drug-resistant cancers 

Current Status

In case of interest we are pleased to inform you about the patent status.

Relevant Publications

Slotta, C., et al. CRISPR/Cas9-mediated deficiency of human IKBK1/IKBK2 leads to TNFα-induced programmed cell death. In preparation

Slotta, C., et al. (2017) CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLoS ONE 12(8): e0182373

Karin, M., et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2(4): 301-10

Mehr Angebote in Pharma